Scarica l'app Stockscreener
12.28
1.21%
-0.12
Precedente Chiudi:
$12.40
Aprire:
$13.19
Volume 24 ore:
3.02M
Relative Volume:
2.18
Capitalizzazione di mercato:
$946.24M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-3.8861
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
+17.90%
1M Prestazione:
+24.62%
6M Prestazione:
+18.24%
1 anno Prestazione:
+10.76%
Intervallo 1D:
$12.03
$13.19
Intervallo di 1 settimana:
$10.20
$13.19
Portata 52W:
$6.44
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Confronta REPL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
12.28 | 719.99M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.40 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.62 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.74 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.28 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.26 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune Group Target of Unusually Large Options Trading (NASDAQ:REPL) - Defense World
Replimune Group’s 8% Spike: A Mystery Unraveled Through Order Flow and Peer Dynamics - AInvest
Why Replimune Group Inc. stock attracts strong analyst attentionCapital Safe Stock Watchlist - Newser
Replimune Group's Mysterious 5.5% Surge: What's Behind the Move? - AInvest
What makes Replimune Group Inc. stock price move sharplyTop ROI Selections - Newser
How Replimune Group Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REPL Stock News - GuruFocus
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stocks Flashing Renewed Technical Strength: Replimune Group - MSN
Replimune Group (REPL) Soars 3.66% on FDA BLA Acceptance - AInvest
H.C. Wainwright reiterates Buy rating on Replimune stock ahead of FDA decision - Investing.com Canada
Replimune’s SWOT analysis: oncology firm’s stock poised for FDA decision By Investing.com - Investing.com South Africa
Replimune Group (NASDAQ:REPL) Given Buy Rating at HC Wainwright - Defense World
REPL Stock Update: HC Wainwright & Co. Reiterates Buy Rating | R - GuruFocus
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
Cantor Fitzgerald reiterates overweight rating on Replimune stock By Investing.com - Investing.com Canada
Replimune Group Hosts Investor Day for Updates - TipRanks
Replimune (REPL) Gains Favorable Outlook Ahead of FDA Decision | REPL Stock News - GuruFocus
GAMMA Investing LLC Boosts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE - Defense World
California State Teachers Retirement System Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 15,402 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Squarepoint Ops LLC Cuts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan - Nasdaq
Replimune Group, Inc. (REPL) Stock Analysis: A Biotech Gem with 124% Potential Upside - DirectorsTalk Interviews
JPMorgan reiterates overweight rating on Replimune stock after ASCO By Investing.com - Investing.com Canada
Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World
Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com South Africa
Piper Sandler raises Replimune stock price target after updates - Investing.com Australia
Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister
Replimune Group (REPL) Price Target Raised by Piper Sandler Anal - GuruFocus
Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus
Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus
BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News - GuruFocus
Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq
Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan
ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World
Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Replimune Group Inc Azioni (REPL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
3.14%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):